Payment overview · 2025
General Payments
$1,638.08
57 reported records · 15 companies
Healthcare provider profile · identity verified
Jonathan Alvior, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TAMPA, FL · NPI 1154513067
Verified facts
What the public records show
CMS Open Payments records show Jonathan Alvior, M.D. received $1,638.08 in general payments during 2025 across 57 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Lokelma, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $373.09 | 22.8% | 15 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $295.23 | 18.0% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $263.79 | 16.1% | 7 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $149.25 | 9.1% | 6 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $134.26 | 8.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $77.31 | 4.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.15 | 4.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.37 | 4.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.25 | 2.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.93 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.35 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.12 | 1.8% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$28.61 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.59 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.78 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,638.08 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $295.23 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $263.79 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $220.99 | 7 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $149.25 | 6 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $134.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $110.18 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $77.31 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.15 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.78 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.95 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $45.76 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.48 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.25 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 519 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 50 |
| Furosemide | Furosemide | 174 | 62 |
| Gabapentin | Gabapentin | 173 | 40 |
| Eliquis | Apixaban | 168 | 35 |
| Lisinopril | Lisinopril | 137 | 46 |
| Losartan Potassium | Losartan Potassium | 130 | 43 |
| Carvedilol | Carvedilol | 123 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 37 |
| Omeprazole | Omeprazole | 110 | 34 |
| Metformin Hcl | Metformin Hcl | 109 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 30 |
| Famotidine | Famotidine | 84 | 25 |
| Montelukast Sodium | Montelukast Sodium | 81 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 22 |
| Potassium Chloride | Potassium Chloride | 74 | 26 |
| Allopurinol | Allopurinol | 72 | 20 |
| Alprazolam | Alprazolam | 72 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 34 |
| Jardiance | Empagliflozin | 66 | 16 |
| Trazodone Hcl | Trazodone Hcl | 65 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Donepezil Hcl | Donepezil Hcl | 57 | 16 |
| Memantine Hcl | Memantine Hcl | 57 | 11 |
| Sertraline Hcl | Sertraline Hcl | 56 | 19 |
| Ezetimibe | Ezetimibe | 51 | 17 |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 14 |
| Finasteride | Finasteride | 47 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Levetiracetam | Levetiracetam | 45 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Lactulose | Lactulose | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 17 |
| Farxiga | Dapagliflozin Propanediol | 42 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 19 |
| Atenolol | Atenolol | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | 17 |
| Methylprednisolone | Methylprednisolone | 35 | 29 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 34 | 14 |
| Prednisone | Prednisone | 33 | 15 |
| Spironolactone | Spironolactone | 33 | 18 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Midodrine Hcl | Midodrine Hcl | 28 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 14 |
| Azithromycin | Azithromycin | 24 | 17 |
| Glipizide | Glipizide | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Kerendia | Finerenone | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 12 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,638.08 · 57 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, FUROSCIX, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND, Zunveyl | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error